Bio Total Current Assets vs Net Debt Analysis
| BPTH Stock | USD 2.81 0.05 1.81% |
Bio Path financial indicator trend analysis is way more than just evaluating Bio Path Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Path Holdings is a good investment. Please check the relationship between Bio Path Total Current Assets and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
Total Current Assets vs Net Debt
Total Current Assets vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Path Holdings Total Current Assets account and Net Debt. At this time, the significance of the direction appears to have pay attention.
The correlation between Bio Path's Total Current Assets and Net Debt is -0.99. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Net Debt in the same time period over historical financial statements of Bio Path Holdings, assuming nothing else is changed. The correlation between historical values of Bio Path's Total Current Assets and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Bio Path Holdings are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Current Assets i.e., Bio Path's Total Current Assets and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.99 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Bio Path's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Path Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. The Bio Path's current Sales General And Administrative To Revenue is estimated to increase to 179.88, while Selling General Administrative is projected to decrease to 3,906.
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 3K | 33K | 52K | 32.5K | Interest Income | 3K | 33K | 52K | 31.0K |
Bio Path fundamental ratios Correlations
Click cells to compare fundamentals
Bio Path Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Path fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 22.7M | 16.5M | 26.6M | 16.0M | 3.2M | 3.1M | |
| Other Current Liab | 673K | 975K | 770K | 909K | 1.3M | 1.4M | |
| Total Current Liabilities | 1.2M | 1.2M | 958K | 1.7M | 1.9M | 2.0M | |
| Total Stockholder Equity | 21.1M | 15.1M | 25.5M | 14.2M | 441K | 419.0K | |
| Property Plant And Equipment Net | 670K | 519K | 428K | 356K | 178K | 344.7K | |
| Net Debt | (20.0M) | (13.4M) | (23.5M) | (10.2M) | (939K) | (986.0K) | |
| Retained Earnings | (56.3M) | (67.2M) | (77.7M) | (91.5M) | (107.6M) | (102.2M) | |
| Accounts Payable | 486K | 100K | 106K | 667K | 457K | 479.9K | |
| Cash | 20.4M | 13.8M | 23.8M | 10.4M | 1.1M | 999.4K | |
| Non Current Assets Total | 670K | 519K | 428K | 356K | 178K | 169.1K | |
| Non Currrent Assets Other | (13.4M) | 288K | 225K | 158K | 76K | 79.8K | |
| Cash And Short Term Investments | 20.4M | 13.8M | 23.8M | 10.4M | 1.1M | 999.4K | |
| Common Stock Shares Outstanding | 132.9K | 192.4K | 336.3K | 363.8K | 478K | 292.6K | |
| Liabilities And Stockholders Equity | 22.7M | 16.5M | 26.6M | 16.0M | 3.2M | 3.1M | |
| Non Current Liabilities Total | 330K | 236K | 153K | 113K | 873K | 916.7K | |
| Other Current Assets | 788K | 2.2M | 2.4M | 5.2M | 2.0M | 2.1M | |
| Other Stockholder Equity | 77.4M | 82.3M | 103.1M | 105.7M | 108.0M | 113.4M | |
| Total Liab | 1.6M | 1.4M | 1.1M | 1.8M | 2.8M | 2.9M | |
| Property Plant And Equipment Gross | 670K | 519K | 1.3M | 1.3M | 1.2M | 1.3M | |
| Total Current Assets | 22.0M | 16.0M | 26.1M | 15.6M | 3.0M | 2.9M | |
| Common Stock | 1K | 4K | 5K | 7K | 8K | 950.0 | |
| Common Stock Total Equity | 11K | 1K | 4K | 5K | 4.5K | 4.3K | |
| Net Tangible Assets | 1.2M | 21.1M | 15.1M | 25.5M | 29.3M | 30.7M | |
| Retained Earnings Total Equity | (39.2M) | (47.7M) | (56.3M) | (67.2M) | (60.5M) | (57.5M) | |
| Capital Surpluse | 47.2M | 49.0M | 77.4M | 82.3M | 94.6M | 99.4M | |
| Property Plant Equipment | 406K | 303K | 231K | 428K | 492.2K | 282.1K | |
| Accumulated Depreciation | (330K) | (592K) | (726K) | (798K) | (718.2K) | (682.3K) | |
| Net Invested Capital | 21.1M | 15.1M | 25.5M | 14.2M | 441K | 419.0K | |
| Net Working Capital | 20.7M | 14.8M | 25.2M | 13.9M | 1.1M | 1.1M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bio Path in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bio Path's short interest history, or implied volatility extrapolated from Bio Path options trading.
Pair Trading with Bio Path
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Path position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will appreciate offsetting losses from the drop in the long position's value.Moving together with Bio Stock
| 0.64 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Bio Stock
| 0.87 | ACRV | Acrivon Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.76 | RVMD | Revolution Medicines Financial Report 13th of May 2024 | PairCorr |
| 0.72 | INDP | Indaptus Therapeutics | PairCorr |
| 0.54 | FBRX | Forte Biosciences Financial Report 20th of May 2024 | PairCorr |
| 0.53 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Bio Path could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Path when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Path - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Path Holdings to buy it.
The correlation of Bio Path is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Path moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Path Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Path can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.63) | Return On Assets (1.03) | Return On Equity (2.20) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.